Drug intelligence / Profile preview

Neuriterx

Development stage
Unknown
Lead developer
Aytu BioPharma
Modality
Small Molecules
Administration
Topical
01

Overview

**Neuriterx** is a topical over-the-counter cream containing **0.05% or 0.075% capsaicin**, a naturally occurring compound derived from chili peppers, formulated for the symptomatic relief of neuropathic pain symptoms such as burning, tingling, numbness, swelling, and poor balance associated with peripheral neuropathy. It acts primarily by activating **transient receptor potential cation channel subfamily V member 1 (TRPV1)** on nociceptive nerve fibers, leading to initial depolarization followed by defunctionalization—a prolonged desensitization that reduces pain signaling through mechanisms including substance P depletion, mitochondrial disruption, and nerve terminal retraction. Developed as a patent-pending neuropathy management product by **Semprae Laboratories Inc.**, it provides rapid relief within minutes of application without systemic absorption risks typical of prescription analgesics.[3][4][6][9]

Brand names
Neuriterx
Other names
Neuriterx 0.05%Neuriterx 0.075%
02

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on Neuriterx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuriterx.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call